NSNasim Camillia Sobhani

Nasim Camillia Sobhani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nasim Camillia Sobhani has a total of 146 co-authors. Here are the top co-authors by number of shared publications:

  • Juan M. Gonzalez

    Pregnancy and Cardiac Treatment Clinic, University of California, San Francisco, California

    5 shared publications
  • Alexander M. Friedman

    Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, New York

    3 shared publications
  • Kartik Kailas Venkatesh

    Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH, United States

    3 shared publications
  • Akshaya Kannan

    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, CA

    2 shared publications
  • Anushree Agarwal

    Division of Cardiology, Department of Internal Medicine, University of California, San Francisco, California

    2 shared publications
  • Anushree Agarwal

    Division of Cardiology, Department of Medicine, University of California, San Francisco, CA (A.A., J.V., L.A.).

    2 shared publications

Latest Publications

  • Open Access

    Digital Cognitive Behavioral Therapy for Insomnia Versus Sleep Hygiene Education for Prevention of Perinatal Depression: Protocol for a Randomized Clinical Trial

    by Jennifer N Felder, Patricia J Moran, Bernadette McClelland, Richelle Mah, Candance Sorensen, Carolyn Ponting, Nasim C Sobhani, John Neuhaus, Andrew Krystal, Rachel Manber

    Background: Insomnia during pregnancy is a modifiable risk factor for depression. Research in nonpregnant populations and preliminary findings in a pregnant population suggest that targeting insomnia with digital cognitive behavioral therapy for insomnia (CBT-I) may prevent depression. Objective: This study aims to evaluate the efficacy of digital CBT-I for the prevention of depression through 12 months post partum compared to that of a credible, clinically relevant comparator intervention, sleep hygiene education (SHE). This project will also provide valuable information about how and for whom CBT-I prevents perinatal depression. Methods: The Perinatal Research for Improving Sleep and Mental Health study is a fully remote, 2-arm parallel-group randomized controlled trial designed to test the superiority of digital CBT-I versus SHE for the prevention of perinatal depression. We aimed to randomize a target sample of at least 443 pregnant participants with insomnia disorder to digital CBT-I or SHE at a 1:1 ratio. Participants randomized to digital CBT-I received SleepioRx (Big Health, Inc), which uses sleep consolidation, stimulus control, cognitive therapy, relaxation techniques, and SHE in 6 interactive modules (5‐15 min each). Participants randomized to SHE received information about sleep hygiene, the impact of sleep on performance, healthy sleep habits, lifestyle influences on sleep, and creating a sleep-friendly bedroom in 6 weekly digital handouts. Data are collected at baseline, 5 weeks after randomization, 10 weeks after randomization, 36 weeks’ gestation, and 3, 6, 9, and 12 months post partum. The primary outcome is depression incidence, measured using the Structured Clinical Interview for DSM-5 ( Diagnostic and Statistical Manual of Mental Disorders [Fifth Edition]) Disorders, Research Version. Other outcome measures include the Edinburgh Postnatal Depression Scale, Patient Health Questionnaire-9, Columbia Suicide Severity Rating Scale, Generalized Anxiety Disorder Scale, and a birth outcomes questionnaire. Mediator measures include the Insomnia Severity Index, Consensus Sleep Diary, Structured Clinical Interview for Sleep Disorders, Perseverative Thinking Questionnaire, Dysfunctional Beliefs about Sleep Scale, Pre-sleep Arousal Scale, and Difficulties in Emotion Regulation-Short Form. Results: Data collection began in November 2022 and is projected to end in December 2026. Conclusions: If study hypotheses are supported, then this project will provide a new, scalable approach for preventing perinatal depression.

  • Perinatal Diabetes Care

    by Nasim C. Sobhani

  • Diabetes Technology Use in Pregnancies with Type 1 Diabetes in the United States from 2009 to 2020

    by Nasim Camillia Sobhani, Yongmei Huang, Kartik Kailas Venkatesh, Jason D. Wright, Alexander M. Friedman, Timothy Wen

    The use of continuous glucose monitors (CGM) and insulin pumps has revolutionized the care of patients with type 1 diabetes (T1D). Few data are available regarding the use of diabetes technology use in the pregnant T1D population. This study was conducted to evaluate temporal trends of diabetes technology use and predictors of use among pregnant individuals with TID in the United States from 2009 to 2020. MarketScan Research Databases from 2009 to 2020 were used to identify pregnant individuals with T1D who were and were not using CGM and/or insulin pumps. Joinpoint regression analysis was used to estimate the average annual percent change (AAPC) in diabetes technology use over time. Unadjusted and adjusted log-linear Poisson regression models were developed to assess the associations between the outcomes of CGM and insulin pump use and demographic and clinical predictors. Associations were reported as adjusted risk ratios (ARR) with 95% confidence intervals (CI). Among 9,201 pregnancies with T1D, CGM use increased from 2.3% in 2009 to 13.7% in 2020 (AAPC: 13.9%; 95% CI: 11.7–17.1), while insulin pump use remained unchanged from 10.9% in 2009 to 11.8% in 2020 (AAPC: −2.4%; 95% CI: −4.4 to 0.4). Medicaid insurance and obesity were associated with a lower likelihood of CGM use and insulin pump use, while a high obstetric comorbidity index score was associated with a higher likelihood of insulin pump use (ARR: 1.26; 95% CI: 1.05–1.51). From 2009 to 2020, CGM use among pregnant individuals with T1D increased, while insulin pump use remained unchanged. Use varied by patient demographic and clinical factors, most notable for lower likelihood of CGM use and insulin pump use with Medicaid insurance. Although CGM use increased over time, overall CGM use remained lower than expected despite the known benefits of CGM use in improving neonatal outcomes in pregnancies complicated by T1D.


  • Open Access

    Impact of Automated Insulin Delivery on Glycemic Profile and Maternal/Neonatal Outcomes in Pregnancy: A Review of the Evidence From Observational Studies

    by Nasim C. Sobhani

    The mainstay of type 1 diabetes (T1D) management in pregnancy is optimization of glucose levels in a tight range. Achieving euglycemia has been revolutionized by advances in diabetes technology, including the development of automated insulin delivery (AID) systems. A small but growing population of gravidas with T1D elects to pursue off-label use of AID systems in pregnancy, and their outcomes have been described in numerous observational cohorts. This review aims to aggregate data from all available observational studies examining glycemic, maternal, and neonatal outcomes associated with antenatal AID use. A total of 243 pregnancies managed antenatally with AID were described in 24 publications, with largely reassuring outcomes data. Time in range (TIR) with commercial AID systems was generally acceptable, with many patients reaching pregnancy target TIR > 70% by the third trimester. Time in range with open-source AID systems appeared even higher, although with the potential tradeoff of worse time below range (TBR). Clinically, there do not appear to be major differences in pregnancy outcomes between AID systems and other methods of insulin delivery, although this assumption is based largely on indirect comparisons with other population-level reports rather than direct comparisons within analytic observational cohorts. Clinical outcomes appear superior with open-source AID compared with commercial AID, although this should be interpreted with caution based on the small sample size of this subpopulation (n = 16) and potential confounding. The real-world evidence generated by these observational studies provides invaluable information for patients and providers seeking to improve outcomes for gravidas with T1D.


  • Incidence of New, Nonphysiologic Maternal Findings on Fetal Magnetic Resonance Imaging

    by Shirley J. Shao, Andrew Grimes, Marley Rashad, Liina Poder, Dorothy Shum, Nasim Camillia Sobhani

    Fetal magnetic resonance imaging (MRI) is increasingly used for evaluation of fetal anomalies, and rates of incidental maternal findings are not well characterized. Our objective was to evaluate the rate of incidental maternal findings at the time of antenatal MRI performed for fetal indications.This was a retrospective cohort study that included all fetal MRIs performed between 2018 and 2023 at a single tertiary care institution with a multidisciplinary fetal diagnosis and treatment center. The electronic medical record was reviewed to identify all documented maternal findings and any new, nonphysiologic maternal findings. The latter was defined as previously unknown abnormalities of maternal structures unrelated to normal physiology.Our study included 834 imaging events, performed at an average gestational age of 23 weeks. The most common indication for imaging was fetal anomaly (81.1%). The most common imaging type was fetal brain MRI (81.4%). Overall, 16.2% reported a maternal finding and 7% reported a new, nonphysiologic finding. The most common new, nonphysiologic findings were renal cysts (n = 11), liver cysts (n = 6), and gallstones or gallbladder sludge (n = 5). Compared with imaging events that included a fetal brain MRI, imaging events that included a fetal body MRI had a significantly higher rate of any maternal findings (53.0 vs. 10.4%, p < 0.001) and new, nonphysiologic maternal findings (26.9 vs. 3.7%, p < 0.001).Our results suggest that the risk of identifying new, nonphysiologic maternal findings on fetal MRI is low. The rate of any maternal and new, nonphysiologic maternal findings may differ by fetal MRI type due to differences in imaging depth and extent of radiology subspecialist review. These data should be incorporated into pretest counseling for patients planning to have fetal MRI.

  • Open Access

    Comparative effectiveness trial of metformin versus insulin for the treatment of gestational diabetes in the USA: clinical trial protocol for the multicentre DECIDE study

    by Kartik K Venkatesh, Cora MacPherson, Rebecca G Clifton, Camille E Powe, Anna Bartholomew, Donna Gregory, Anne Trinh, Ann Scheck McAlearney, Lauren G Fiechtner, Patrick Catalano, et al.

    Introduction Gestational diabetes mellitus (GDM) is one of the most common medical complications of pregnancy. Glycaemic control decreases the risk of adverse pregnancy outcomes for the affected pregnant individual and the infant exposed in utero. One in four individuals with GDM will require pharmacotherapy to achieve glycaemic control. Injectable insulin has been the mainstay of pharmacotherapy. Oral metformin is an alternative option increasingly used in clinical practice. Both insulin and metformin reduce the risk of adverse pregnancy outcomes, but comparative effectiveness data from a well-characterised, adequately powered study of a diverse US population remain lacking. Because metformin crosses the placenta, long-term safety data, in particular, the risk of childhood obesity, from exposed children are also needed. In addition, the patient-reported experiences of individuals with GDM requiring pharmacotherapy remain to be characterised, including barriers to and facilitators of metformin versus insulin use. Methods and analysis In a two-arm open-label, pragmatic comparative effectiveness randomised controlled trial, we will determine if metformin is not inferior to insulin in reducing adverse pregnancy outcomes, is comparably safe for exposed individuals and children, and if patient-reported factors, including facilitators of and barriers to use, differ between metformin and insulin. We plan to recruit 1572 pregnant individuals with GDM who need pharmacotherapy at 20 US sites using consistent diagnostic and treatment criteria for oral metformin versus injectable insulin and follow them and their children through delivery to 2 years post partum. More information is available at www.decidestudy.org. Ethics and dissemination The Institutional Review Board at The Ohio State University approved this study (IRB: 2024H0193; date: 7 December 2024). We plan to submit manuscripts describing the results of each study aim, including the pregnancy outcomes, the 2-year follow-up outcomes, and mixed-methods assessment of patient experiences for publication in peer-reviewed journals and presentations at international scientific meetings. Trial registration number NCT06445946.


  • Immediate Postpartum Breastfeeding following Pregnancy with Cardiac Disease

    by Yolanda Tinajero, Nisha I. Parikh, Ian S. Harris, Juan M. Gonzalez, Anushree Agarwal, Nasim C. Sobhani

    Objective This study aimed to identify predictors of immediate postpartum breastfeeding among women with maternal cardiac disease (MCD). Study Design This study included all gravidas with MCD who delivered at a single institution from 2012 to 2018. Charts were abstracted for maternal demographics, obstetrical outcome, cardiac diagnoses, cardiac risk stratification scores, and prepregnancy echocardiogram findings. Kruskal–Wallis and Fisher's exact tests were used to compare the breastfeeding (BF) group versus the nonbreastfeeding (NBF) group. Logistic regression was used to obtain odds ratios (ORs) with 95% confidence intervals (CIs). Results Among 211 gravidas with MCD, 12% were not breastfeeding at the time of postpartum hospital discharge. Compared with the BF group, the NBF group had a significantly higher proportion of women with cardiomyopathy (21% NBF vs. 7% BF, OR = 3.44, 95% CI: 1.12–10.71), with modified World Health Organization (WHO) classification ≥III (33 vs. 14%, OR = 3.16, 95% CI: 1.22–8.15), and with prepregnancy ejection fraction (EF) < 50% (55 vs. 14%, OR = 7.20, 95% CI: 1.92–27.06). There were otherwise no differences between the two groups with regards to other cardiac diagnoses or cardiac risk scores. Conclusion In women with MCD, cardiomyopathy, modified WHO class ≥III, and a prepregnancy EF < 50% were associated with NBF in the immediate postpartum period. These findings may guide providers in identifying a subset of women with MCD who can benefit from increased breastfeeding counseling and support. Key Points


  • Continuous glucose monitoring in pregnancies with type 1 diabetes: small increases in time-in-range improve maternal and perinatal outcomes

    by Nasim C. Sobhani, Sophie Goemans, Antoinette Nguyen, Melissa E. Chambers, Michael Richley, Lauryn C. Gabby, Nancy Field, Christina S. Han, Gladys A. Ramos